Valuation: Rekah Pharmaceutical Industry Ltd.

Market Cap 124M 0 40.43M 35.15M 32.71M 30.04M 56.72M 3.86B 57.6M 386M 151M 1.92B 152M 149M 6.44B P/E 2024
24.5x
P/E 2025 -6.91x
Enterprise Value 252M 0 82.18M 71.44M 66.5M 61.05M 115M 7.85B 117M 784M 308M 3.91B 309M 302M 13.1B EV / Sales 2024
0.87x
EV / Sales 2025 0.84x
Free-Float
17.21%
Yield 2024 *
-
Yield 2025 -
05-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-29 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-30 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-25 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-28 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-27 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-03-26 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
23-11-28 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-08-31 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
23-05-29 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
1 day-1.99%
1 week-1.00%
1 month-0.73%
3 months-4.40%
6 months-7.57%
Current year-0.73%
1 week 1,062
Extreme 1062
1,144
1 month 1,006
Extreme 1006
1,144
Current year 1,006
Extreme 1006
1,348
1 year 1,006
Extreme 1006
1,348
3 years 1,006
Extreme 1006
1,788
5 years 1,006
Extreme 1006
2,610
10 years 1,006
Extreme 1006
4,076
Manager TitleAgeSince
Chief Executive Officer 82 1993-08-23
Director of Finance/CFO 46 2018-10-31
President 80 2010-06-27
Director TitleAgeSince
Chairman 82 2010-06-24
Director/Board Member 80 -
Chairman 80 2015-04-14
Change 5-day change 1-year change 3-year change Capi.($)
-1.99%-1.00%-8.66%-31.87% 40.43M
-1.08%+1.82%+22.52%+111.39% 100B
+1.30%+0.88%+47.46%+151.01% 53.87B
-0.68%+3.52%+2.80%+274.52% 23.74B
+0.60%+2.93%-12.64%-16.12% 8.37B
-1.29%+1.85%-33.43%-30.57% 7.56B
-1.53%+3.21%-7.75%-30.20% 6.92B
-1.14%-1.47%+23.29%+22.85% 6.16B
-1.83%-0.87%-0.52%+22.61% 5.29B
-.--%+2.79%-6.02%-3.62% 3.8B
Average -0.76%+1.08%+2.70%+47.00% 21.6B
Weighted average by Cap. -0.40%+1.64%+21.23%+118.01%

Financials

2024 2025
Net sales 322M 0 105M 91.21M 84.9M 77.95M 147M 10.02B 149M 1B 393M 4.99B 394M 385M 16.72B 301M 0 98.17M 85.34M 79.43M 72.93M 138M 9.37B 140M 936M 367M 4.67B 369M 361M 15.64B
Net income 6.21M 0 2.02M 1.76M 1.64M 1.5M 2.84M 193M 2.88M 19.31M 7.58M 96.2M 7.6M 7.43M 323M -18.07M -0 -5.89M -5.12M -4.77M -4.38M -8.27M -563M -8.4M -56.22M -22.07M -280M -22.14M -21.65M -939M
Net Debt 127M 0 41.45M 36.03M 33.54M 30.79M 58.15M 3.96B 59.05M 395M 155M 1.97B 156M 152M 6.61B 128M 0 41.75M 36.3M 33.78M 31.02M 58.57M 3.99B 59.48M 398M 156M 1.98B 157M 153M 6.65B
Logo Rekah Pharmaceutical Industry Ltd.
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Employees
390
Date Price Change Volume
26-07-31 ILA 1,086.00 -1.99% 3,403
26-07-30 ILA 1,108.00 +1.47% 9,576
26-07-29 ILA 1,092.00 +1.30% 95
26-07-28 ILA 1,078.00 +0.94% 1,207
26-07-27 ILA 1,068.00 -2.64% 1,114
  1. Stock Market
  2. Stocks
  3. REKA Stock